Company profile
Therapeutic Solutions International, Inc.
OTC: TSOI · Healthcare · Biotechnology
#1043 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 46GM —SS 37
v0.1 · 25/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$85.3k
Rev growth YoY (TTM)
+1.9%
Net income (FY)
-$2.2M
Employees
3
as of 2026-08-27
Market cap
$512.3k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$99.0k$99.0k2023
Net income-$2.2M-$2.2M2023
Operating income-$2.0M-$2.0M2023
Total assets$3.3M$3.3M2023
Liabilities$2.0M$2.0M2023
Equity$1.1M$1.1M2023
Revenue trend
FY2017 – FY2023 · USD
FY17
FY17
FY18
FY19
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Therapeutic Solutions International, Inc.’s revenue?
Therapeutic Solutions International, Inc. booked $99.0k in FY2023 revenue, contracting 52% year over year — slower than 82% of Healthcare companies we track, at a -2191.9% net margin.
Peers · Healthcare
Finch Therapeutics Group, Inc.——Meridian Holdings, Inc.——Profusa, Inc. Common Stock9DAllied Corp.——Actinium Pharmaceuticals, Inc.28DCitius Pharmaceuticals, Inc.42DKey facts
CEOTimothy George Dixon
SectorHealthcare
IndustryBiotechnology
HeadquartersElk City, ID
ExchangeOTC: TSOI
Employees3
IPO date2008-06-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.